Lymphoma

Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.

Lymphoma survivor Nina Luker talks about receiving a diagnosis at age 24 and how sharing her story with nearly 200,000 supporters on social media helped her find purpose.

Early findings show that glofitamab may be a safe and effective option for patients with pretreated, relapsed/refractory B-cell non-Hodgkin lymphoma.

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival.

Throughout the winter, the FDA has continued to approve several new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

As part of its Speaking Out video series, CURE® spoke with Dr. Steven M. Horwitz on behalf of the Cutaneous Lymphoma Foundation about cutaneous T-cell lymphoma and options for treatment.

One patient with breast implant-associated anaplastic large cell lymphoma spoke out for herself throughout therapy — and encourages other patients do the same.

The Food and Drug Administration on Friday approved Breyanzi, a cell-based gene therapy, for the treatment of adults with certain types of large B-cell lymphoma.

This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.

Patients with aggressive lymphomas experienced sharp increases in quality of life from time of diagnosis until one year later and continued to see improvements for almost a decade.

Study results also determined that immune system status before treatment may predict outcomes post-treatment.

Doctors told Maryland Governor Larry Hogan to go home and rest after undergoing cancer surgery. But he had other plans: sharing his health issues.

From acclaimed actor Jeff Bridges tweeting about a new lymphoma diagnosis to controversial conservative radio host Rush Limbaugh announcing that his stage 4 lung cancer has progressed, here’s what’s happening in the cancer landscape this week.

Data from the trial that led to the FDA approval demonstrated that Keytruda reduced the risk of progression or death in patients with relapsed or refractory classical Hodgkin lymphoma by 35%, compared to Adcetris.

In an interview with CURE®, the president of the National Center for Health Research elaborates on the effort to protect patients from potentially serious side effects associated with getting breast implants, including breast implant-associated anaplastic large cell lymphoma.

New guidance from the Food and Drug Administration recommends that the makers of breast implants include a black-box warning, a patient decision checklist and other information on product labels that will help protect them against a cancer and an autoimmune condition that can arise from use of the devices.

In this special hematology focused issue of CURE® we look at all the promising treatments and research for both adults and children with blood cancers.

Weighing the cost of CAR-T cell therapy in treating blood cancers is a finical burden for many patients with blood cancer.

Susan M. O’Brien, M.D., one of the nation’s foremost leukemia experts, discusses the future of frontline therapies and upcoming clinical trials associated with chronic lymphocytic leukemia.

CURE® compiled a roundup of five recent reports patients with lymphoma may have missed.

The FDA also released a video for patients that details seven things they should know about breast implants, including information about breast implant-associated lymphoma and systemic symptoms.